Global Alpha Capital Management Ltd. Purchases 2,160 Shares of Pacira BioSciences, Inc. (NASDAQ:PCRX)

Global Alpha Capital Management Ltd. raised its position in shares of Pacira BioSciences, Inc. (NASDAQ:PCRX) by 5.7% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 39,900 shares of the company’s stock after purchasing an additional 2,160 shares during the period. Global Alpha Capital Management Ltd.’s holdings in Pacira BioSciences were worth $752,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds have also made changes to their positions in the company. Caitlin John LLC increased its stake in shares of Pacira BioSciences by 1,850.0% during the fourth quarter. Caitlin John LLC now owns 1,872 shares of the company’s stock valued at $35,000 after buying an additional 1,776 shares during the period. Nisa Investment Advisors LLC grew its holdings in Pacira BioSciences by 495.3% during the 4th quarter. Nisa Investment Advisors LLC now owns 3,304 shares of the company’s stock worth $62,000 after acquiring an additional 2,749 shares in the last quarter. Virtus Investment Advisers Inc. purchased a new position in Pacira BioSciences during the 3rd quarter valued at about $98,000. Quest Partners LLC raised its holdings in shares of Pacira BioSciences by 137.6% in the 3rd quarter. Quest Partners LLC now owns 9,410 shares of the company’s stock valued at $142,000 after purchasing an additional 5,449 shares in the last quarter. Finally, China Universal Asset Management Co. Ltd. lifted its position in shares of Pacira BioSciences by 10.3% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 9,790 shares of the company’s stock worth $184,000 after purchasing an additional 918 shares during the period. 99.73% of the stock is currently owned by hedge funds and other institutional investors.

Pacira BioSciences Price Performance

Shares of PCRX stock opened at $23.37 on Friday. The firm has a market capitalization of $1.08 billion, a price-to-earnings ratio of -11.51 and a beta of 0.86. The company has a debt-to-equity ratio of 0.51, a quick ratio of 1.89 and a current ratio of 2.25. The stock’s 50-day simple moving average is $23.55 and its 200-day simple moving average is $18.94. Pacira BioSciences, Inc. has a fifty-two week low of $11.16 and a fifty-two week high of $31.67.

Wall Street Analysts Forecast Growth

PCRX has been the subject of a number of recent research reports. Royal Bank of Canada reissued a “sector perform” rating and issued a $18.00 price objective on shares of Pacira BioSciences in a research note on Tuesday, January 14th. Needham & Company LLC boosted their price target on Pacira BioSciences from $30.00 to $32.00 and gave the stock a “buy” rating in a research report on Friday, February 28th. Truist Financial upgraded Pacira BioSciences from a “sell” rating to a “hold” rating and upped their price objective for the stock from $8.00 to $25.00 in a research note on Thursday, January 30th. Barclays lifted their target price on Pacira BioSciences from $17.00 to $24.00 and gave the company an “overweight” rating in a research note on Friday, February 28th. Finally, HC Wainwright increased their price target on shares of Pacira BioSciences from $57.00 to $70.00 and gave the company a “buy” rating in a research report on Friday, February 28th. One equities research analyst has rated the stock with a sell rating, four have given a hold rating and five have given a buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average target price of $27.22.

About Pacira BioSciences

Pacira Biosciences, Inc is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients’ journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam. The company was founded in December 2006 and is headquartered in Tampa, FL.